BRAF and neoplasm: Notably, the tumor-agnostic approval of dabrafenib (a BRAF inhibitor) in combination with trametinib (a MEK inhibitor) for BRAF V600E–mutant cancers explicitly excludes CRCs due to known intrinsic resistance (Gouda & Subbiah 2023).